The Latest Breaking News on Pharma

Up to one in five people are suffering with diarrhoea, according to a new report

Australian researchers are designing a vaccine specifically targeting transmissibility which could be variant-proof and won’t require updates.

Health Canada says it secured a foreign supply of children’s acetaminophen that will be for sale ‘in the coming weeks’

The U.S. chemical industry, one of the world’s largest, has rebounded post-pandemic, driven by solid demand. Hence, sound chemical stock American Vanguard (AVD) might be an ideal investment. However, the industry is under pressure because of carbon emissions, supply chain challenges, and high input costs. And we believe Gevo (GEVO)…

NEW YORK — Walmart agreed to pay $3.1 billion to resolve lawsuits accusing the pharmacy of selling drugs that contributed to the opioid epidemic, but denied the allegations and didn’t admit liability.

Amid job losses and tumbling share prices, all the platforms once thought too big to fail are now fighting to stay relevant. From Twitter to Meta, change is afoot, says John Arlidge

Biopharma giant AbbVie (ABBV) is well-placed to gain from its drug pipeline, recent drug approvals, and strategic acquisitions. Given its strong fundamentals, discounted valuation, high profitability, reliable dividends, and favorable analyst estimates, investing in this stock could help you retire earlier. Read more.

The retail giant becomes the latest major player in the drug industry to announce a plan to settle lawsuits filed by state and local governments over the toll of opioids sold at its pharmacies.

Walmart said that the proposed framework "does not include any admission of liability."